Clinical trials: Hematologic Disorders
Hodgkin Disease, Lymphoma, Non-Hodgkin
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Trial name
- NCT00275262
- Testing
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
Sickle Cell Disease
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD).
- Trial name
- ViSionSerenity (NCT04817670)
- Testing
- VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 25 people
- Sponsor
- Vifor (International) Inc.
Eosinophilic Esophagitis (EoE)
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
This is a randomized, placebo-controlled, parallel-arm, dose-ranging study in subjects with eosinophilic esophagitis, 2-18 years of age. Eligible subjects will be randomized into one of four treatment groups.
- Trial name
- NCT00762073
- Testing
- budesonide
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Shire
Anemia, Sickle Cell
Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes.
- Trial name
- Arginine (NCT00513617)
- Testing
- Arginine
- Where
- 17 sites in United States
- Volunteers
- 128 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Congenital Hemophilia A
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A
This is an international, multicenter, open-label study to assess the efficacy, safety, and pharmacokinetic (PK) profile of rVIII-SingleChain in pediatric patients with severe hemophilia A.
- Trial name
- NCT02093897
- Testing
- rVIII-SingleChain
- Where
- 37 sites in United States, Australia and 17 more
- Volunteers
- 84 people
- Sponsor
- CSL Behring
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
Myelodysplastic Syndrome, Acute Myeloid Leukemia
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
- Trial name
- NCT00774046
- Testing
- Ara-C, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well lenalidomide and nivolumab work in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03333746
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yvonne Efebera
Leukemia
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268242
- Testing
- Gemcitabine Hydrochloride, Mitoxantrone Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- The Cleveland Clinic
Lymphoma
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients…
- Trial name
- NCT00052442
- Testing
- pralatrexate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Sickle Cell Anemia
Haploidentical PBMC Transplant for Severe Congenital Anemias
Background: Bone marrow transplantation (BMT), which involves transplanting a donor's marrow stem cells, is capable of curing some congenital anemias.
- Trial name
- NCT00977691
- Testing
- PBSC Transplant, Alemtuzumab, Sirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Waldenstrom's Macroglobulinemia
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
Carfilzomib is a drug that has shown anti-tumor activity by inhibiting the proteasome within the cell, which is responsible for degrading or breaking down a wide variety of proteins. Carfilzomib has not been approved by the FDA.
- Trial name
- CaRD (NCT01470196)
- Testing
- Dexamethasone, Carfilzomib, Rituximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Myelodysplastic Syndromes, Anemia
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS).
- Trial name
- NCT00695396
- Testing
- Epoetin alfa
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Myeloid Leukemia
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
This trial studies the side effects of nivolumab in combination with decitabine and venetoclax and to see how well they work in treating patients with TP53-mutated acute myeloid leukemia.
- Trial name
- NCT04277442
- Testing
- Decitabine, Nivolumab, Venetoclax
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Idiopathic Thrombocytopenic Purpura
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic purpura (ITP) .
- Trial name
- NCT00603642
- Testing
- AMG 531
- Volunteers
- 34 people
- Sponsor
- Amgen
Hematologic Malignancies, Relapse
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by…
- Conditions
- Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
- Trial name
- NCT02145403
- Testing
- Carfilzomib, Tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acquired Thrombotic Thrombocytopenic Purpura
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP.
- Trial name
- TITAN (NCT01151423)
- Testing
- Caplacizumab
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Ablynx, a Sanofi company
Multiple Myeloma
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well…
- Trial name
- DFCI 10-106 (NCT01208662)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 46 sites in United States
- Volunteers
- 729 people
- Sponsor
- Paul Richardson, MD
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer.
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05246670
- Testing
- Palmidrol, Quality-of-Life Assessment
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- Academic and Community Cancer Research United
Relapsed/Refractory Multiple Myeloma
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma…
- Trial name
- Bellini (NCT02755597)
- Testing
- Venetoclax, Bortezomib, Dexamethasone
- Where
- 97 sites in United States, Australia and 14 more
- Volunteers
- 291 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.